AB0401 SWITCH FROM ETANERCEPT ORIGINATOR TO ETANERCEPT BIOSIMILAR: DATA FROM REAL LIFE
Sign Up to like & getrecommendations! Published in 2019 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2019-eular.7809
Abstract: Background: Biosimilars of antiTNF-α are now available for the treatment of arthritis. There are a lot of data about maintenance of clinical efficacy after switching from originator to biosimilar but also reports about flares and… read more here.
Keywords: originator; etanercept originator; switch; disease ... See more keywords
AB0217 NON MEDICAL SWITCH FROM ETANERCEPT ORIGINATOR TO BIOSIMILAR GP2015 IN PATIENTS WITH CHRONIC INFLAMMATORY ARTHROPATHIES
Sign Up to like & getrecommendations! Published in 2021 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2021-eular.1557
Abstract: In the last decades, new biologic drugs were introduced for the treatment of chronic inflammatory arthropathies, progressively leading to a relevant increase of medical costs. However, the introduction of biosimilars (biologic molecules similar to branded… read more here.
Keywords: switch; originator biosimilar; etanercept originator; biosimilar gp2015 ... See more keywords